Chongqing Zhifei Bio Products (300122)

Currency in CNY
23.55
-0.53(-2.20%)
Closed·
300122 Scorecard
Full Analysis
Has raised its dividend for 3 consecutive years
High dividend Yield
300122 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23.4224.14
52 wk Range
18.7040.43
Key Statistics
Bid/Ask
23.52 / 23.55
Prev. Close
24.08
Open
23.92
Day's Range
23.42-24.14
52 wk Range
18.7-40.43
Volume
46.48M
Average Volume (3m)
33.92M
1-Year Change
-11.38%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
300122 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.73
Upside
+26.26%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Chongqing Zhifei Bio Products News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Chongqing Zhifei Bio Products Company Profile

Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal Polysaccharide Vaccine under the Menwayc brand; Mycobacterium Vaccae for Injection under the Vaccae brand; Meningococcal Group A and Group C Polysaccharide Conjugate Vaccine under the Mening A Con brand; and other developed products. It also provides cold storage services. Chongqing Zhifei Biological Products Co., Ltd. was founded in 2002 and is based in Chongqing, China.

Employees
7220
Market
China

Compare 300122 to Peers and Sector

Metrics to compare
300122
Peers
Sector
Relationship
P/E Ratio
225.5x35.3x−0.5x
PEG Ratio
−2.33−1.310.00
Price/Book
1.9x2.5x2.6x
Price / LTM Sales
3.4x7.8x3.3x
Upside (Analyst Target)
21.3%1.2%42.8%
Fair Value Upside
Unlock9.6%6.5%Unlock

Analyst Ratings

6 Buy
0 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 29.73
(+26.26% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.11%
Dividend Yield
4.15%
Industry Median 1.51%
Annualised payout
1.00
Paid annually
5-Years Growth
-9.71%
Growth Streak

Earnings

Latest Release
Apr 21, 2025
EPS / Forecast
-0.13 / 0.48
Revenue / Forecast
2.37B / 6.32B
EPS Revisions
Last 90 days

300122 Income Statement

FAQ

What Stock Exchange Does Chongqing Zhifei Bio Products Trade On?

Chongqing Zhifei Bio Products is listed and trades on the Shenzhen Stock Exchange stock exchange.

What Is the Stock Symbol for Chongqing Zhifei Bio Products?

The stock symbol for Chongqing Zhifei Bio Products is "300122."

What Is the Chongqing Zhifei Bio Products Market Cap?

As of today, Chongqing Zhifei Bio Products market cap is 56.47B.

What Is Chongqing Zhifei Bio Products's Earnings Per Share (TTM)?

The Chongqing Zhifei Bio Products EPS (TTM) is 0.11.

When Is the Next Chongqing Zhifei Bio Products Earnings Date?

Chongqing Zhifei Bio Products will release its next earnings report on 23 Oct 2025.

From a Technical Analysis Perspective, Is 300122 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Chongqing Zhifei Bio Products Stock Split?

Chongqing Zhifei Bio Products has split 3 times.

How Many Employees Does Chongqing Zhifei Bio Products Have?

Chongqing Zhifei Bio Products has 7220 employees.

What is the current trading status of Chongqing Zhifei Bio Products (300122)?

As of 06 Aug 2025, Chongqing Zhifei Bio Products (300122) is trading at a price of 23.55, with a previous close of 24.08. The stock has fluctuated within a day range of 23.42 to 24.14, while its 52-week range spans from 18.70 to 40.43.

What Is Chongqing Zhifei Bio Products (300122) Price Target According to Analysts?

The average 12-month price target for Chongqing Zhifei Bio Products is CNY29.73333, with a high estimate of CNY45 and a low estimate of CNY18. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +26.26% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.